Das Blaue Buch 2007 - 2008: Chemotherapie-Manual Hämatologie und internistische Onkologie
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Language: | German |
| Published: |
Heidelberg
Springer
2007
|
| Edition: | 1. Aufl., 1. korrigierter Nachdr. |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis Klappentext |
| Physical Description: | XVIII, 202 S. Ill., graph. Darst. 1 CD-ROM (12 cm) |
| ISBN: | 9783540452829 3540452826 |
Staff View
MARC
| LEADER | 00000nam a22000001c 4500 | ||
|---|---|---|---|
| 001 | BV023353369 | ||
| 003 | DE-604 | ||
| 005 | 20080813 | ||
| 007 | t | ||
| 008 | 080619s2007 gw ad|| |||| 00||| ger d | ||
| 020 | |a 9783540452829 |9 978-3-540-45282-9 | ||
| 020 | |a 3540452826 |9 3-540-45282-6 | ||
| 020 | |z 354045282X |9 3-540-45282-X | ||
| 035 | |a (OCoLC)76873842 | ||
| 035 | |a (DE-599)BVBBV023353369 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a ger | |
| 044 | |a gw |c XA-DE-BE | ||
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994061 |2 22/ger | |
| 084 | |a XH 1503 |0 (DE-625)152870:12909 |2 rvk | ||
| 084 | |a XH 3209 |0 (DE-625)152888:12915 |2 rvk | ||
| 084 | |a YC 2109 |0 (DE-625)153197:12915 |2 rvk | ||
| 084 | |a YC 2303 |0 (DE-625)153200:12909 |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Berger, Dietmar Paul |e Verfasser |0 (DE-588)111674808 |4 aut | |
| 245 | 1 | 0 | |a Das Blaue Buch 2007 - 2008 |b Chemotherapie-Manual Hämatologie und internistische Onkologie |c Dietmar Berger ; Monika Engelhardt ; Roland Mertelsmann |
| 250 | |a 1. Aufl., 1. korrigierter Nachdr. | ||
| 264 | 1 | |a Heidelberg |b Springer |c 2007 | |
| 300 | |a XVIII, 202 S. |b Ill., graph. Darst. |e 1 CD-ROM (12 cm) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Antineoplastic Agents |x therapeutic use | |
| 650 | 4 | |a Antineoplastic Protocols | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Onkologie |0 (DE-588)4075658-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Blutkrankheit |0 (DE-588)4007281-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Hämatologie |0 (DE-588)4022796-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Blutkrankheit |0 (DE-588)4007281-2 |D s |
| 689 | 0 | 1 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Hämatologie |0 (DE-588)4022796-0 |D s |
| 689 | 1 | 1 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Onkologie |0 (DE-588)4075658-0 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 3 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 3 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Engelhardt, Monika |d 1966- |e Verfasser |0 (DE-588)113263538 |4 aut | |
| 700 | 1 | |a Mertelsmann, Roland |d 1944- |e Verfasser |0 (DE-588)122802187 |4 aut | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016536946&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016536946&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |3 Klappentext |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016536946 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
Record in the Search Index
| _version_ | 1804137712279617536 |
|---|---|
| adam_text | Inhaltsverzeichnis
Vorwort..........................................
V
Autorenverzeichnis................................
X
Abkürzungsverzeichnis...........................
XI
Einleitung......................................XIII
Teii
І
Hämatologische Neoplasien
1 Akute Leukämien
1.1 ALL
GMALL B-ALL/NHL 2002 (060101_0360) ...........4
GMALL 07/03 (060101_0400)......................9
GMALL 07/2003 + Rituximab (060101_0458)...... 15
Imatinib bei Ph+ALL (060101_0521 )..............20
Busulfan/Cyclophosphamid/auto
(990000_05)...................................196
1.2 AML
AML99(060102_0155)
IVA-1........................................23
IVA-2........................................23
Flag-Ida
.....................................24
ID-AraC/DNR................................24
HD-AraC/DNR...............................25
Intergroup: Induktion (AraC/DNR)............25
Intergroup: Postremission (HD-AraC).........26
S-HAM (060102_01).............................26
Ida/Ara 3+7 (060102_02)........................27
Ida/Ara 3+4 (060102_03)........................27
MICE
(060102_05) ..............................28
mini-ICE (060102_06) ...........................28
APL2000 (060102_07)...........................29
APL2000 Studie (060102_0220)..................32
Decitabine (060102_0331).......................37
Mylotarge-Studie (060102_0391)................39
AMLSG 7-04-Studie (060102_0478) ..............41
Busulfan/Cyclophosphamid/auto
(990000_05)...................................192
Busulfan mono p.o. (990000_12)................194
Busulfan mono i.v. (990000_15).................
1
94
2 MDS
Decitabine/DAC (EORTC-Studie)
(060200ЈШЗ)
..................................48
Azacytidine (060200_01)........................48
Treosulfan-Studiefremdallogen/familiär
(990000J442) ................................198
3 MPS
3.1 OMF
Thalidomid/Prednison (060510_01)..............50
3.2 CML
GEIST-Studie (060510_0439) ....................50
Busulfan/Cyclophosphamid/auto (990000_05)... 192
4 Hodgkin-Lymphome
ABVD
(060400ЈЛ)
..............................56
BEACOPP-Il-Basis (060400 J)153).................56
BEACOPP-ll-gesteigert (060400_0154) ...........57
HD-13 (060400_0388)...........................57
HD-14 (060400JB89)...........................59
HD-15 (060400_0390)...........................61
PVAG (060400_0446)............................62
Vinblastin (060400_02)..........................62
Bendamustin (060501_11) ......................72
Lomustin (080201_06)..........................110
BEAM (990000_03)
.............................190
BEAM
+
Palìfermin (990000_0322)
..............190
BM (ab 66 Jahre) (990000J3)...................191
5 Non-Hodgkin-Lymphome
CHOP
(0б0501_02)..............................
67
CORAL-Studie (060501_0407)....................72
GMALL B-ALL/NHL 2002
(ОбОЮЦВбО)
............4
FludyCy (MDAnderson) (060502_03).............80
VCP-E (980000_02).............................184
VIP
-Е
(980000_03)..............................184
Cyclo-Mob-Id (980000_05)....................185
Cyclo-Mob^d (980000_06).....................185
BEAM (990000_03)
.............................190
BEAM
+ Palifermin
(990000ЈШ2)
..............190
BM (ab 66 Jahre) (990000_13)...................191
5.1 Mantelzelllymphom
MCLyounger-Studie (060501_0461)............191
Temsirolimus (060505J3459).....................86
5.2 Hochmaligne NHL
VACOP-B
(OóOSOIJJI)
...........................66
CHOP (060501_02)
..............................67
Mabtherae-CHOPM (O6O5O1_O5)................68
CHOP-14 (060501_09)...........................68
CHOP gesplittet
(060501_12)....................69
R-CHOP (060501_14)............................69
COP
(060501_03)................................
70
HD-Pred
(060501_06)............................
70
DHAP
(060501_08)
..............................71
Ixoten® (060501_10)
............................71
Bendamustin
(0б0501_Л
).......................72
CORAL
Studie (060501_0407) ...................72
MCL
younger
(060501_0461)...................192
Flyer Studie (060501_0504) .....................74
Unfolder Studie
(0б0501_0505)
..................76
FludyCy (MDAnderson) (060502_03).............80
Fludara«/Endoxan®/Rituximab
(060502_06)....................................80
5.3 CLL
Knospe (060502_01)............................79
Fludarabin (060502_02).........................79
FludyCy (MDAnderson) (060502_03).............80
Fludarae/Endoxans/Rituximab (060502_06)......80
COP
(060501_03)................................
70
Inhaltsverzeichnis
VII
Bendamustin
(0б0501_1
1).......................72
MabCampath®
(0б0502_04)
.....................81
MabCampath
Studie
(0б0502_0372)
.............81
2-CDA
(0б0504_01)
..............................83
5.4
PLL
CHOP (060501_02)
..............................67
FludyCy (MDAnderson) (060502_03)
.............80
Fludarae/Endoxane/Rituximab (060502_06)
......80
2-CDA
(060504ЈЛ)
..............................83
5.5 Haarzellleukämie
2-CDA
(060504ЈЛ)
..............................83
Pentostatin (060504_02
)........................83
Cladribine/Rituximab (060504_0473)
.............84
5.6
Follikulare NHL
Rituximab (060505_01)
..........................85
CHOP (060501_02)
..............................67
Münchner Lymphomstudie
(MabtheraeCHOP)
(060505_0206)
.................................85
VACOP-B
(0605001)...........................66
COP (060501_03)
................................70
Zevalin®
+
Rituximab (060505_0443)
.............86
Knospe (060502_01) ............................79
Fludarabin (060502_02)
.........................79
Fludara®/Endoxan®/Rituximab
(0б0502_0б)
......80
5.7
Kutané
Т
-NHL
CHOP (060501_02)
..............................67
COP (060501JB)
................................70
Fludarabin (060502_02)
.........................79
2-CDA
(060504ЈЛ)
..............................83
5.8
ZNS-NHL
ZNS-NHL HD 1
8-65J. (060507_02)
...............196
ZNS-NHL >65J.
(060507ЈЛ67)
...................89
ZNS-NHL MTX
(060507_02)
......................88
ZNS-NHL AraCAhiotepa (060507_02)
............88
R-MCP (060507_03)
.............................89
MTX 8g
Hochberg (060507_01)..................90
ZNS-NHL Leukovorin Rescue
.....................90
5.9
Multiples Myelom/Amyloidose
HD-Dexa (060509_02)
...........................91
Alexanian (060509_01)
..........................91
Melphalan (060509_03)
.........................92
Thalidomid/Dexamethason (060509_07)
.........92
CTD (060509_08)
................................93
Lenalidomid/Dexamethason (060509_14)
........93
Velcade^/Bortezomib (060509_1
0)...............94
Bortezomib/Dexamethason (060509_1
2).........94
DeCyBo (060509_1
1)............................95
VAD
(060509__04)
................................
95
Induktion
(Cyclo) (060509_05)
...................96
ID
..............................................96
DSMM Xla (060509_0497)
.......................97
Palladini Protokoll (060509_13)..................98
Amyloidose (HD-Dexa/lnterferon-a)
(060509_09)
....................................98
Bendamustin
(060501_11)
.......................72
Cyclo-Mob-Id (980000_05)
....................185
Cyclo-Mob^d (980000_06)
.....................185
IEV
<
60J. (980000_09)
.........................186
HD
Melphalan
..................................95
ATG/Flu/Mel
...................................200
Aplastische Anämien
CyA/ALG/Prednisolon (070200_01)
.............100
Teil 11 Solide Tumoren
7 Kopf-Hals Tumoren
Doxetaxel/Cisplatin (080100_06) ...............104
S-FU/Cisplatin (080100_04) ....................104
S-FU/Carboplatin (080100_01)..................105
EMB (080100_02) ..............................105
Taxol® (080100_03)............................106
8 Thorakale Tumoren
8.1 SCLC
TEC
(080201 _07)...............................108
Epi-CO (080201 _01 )............................108
Cisplatin/Etoposid
limited disease
(080201_02)...................................109
CE
(080201 _03)................................109
Topotecan (080201_05).........................110
Lomustin (080201_06)..........................110
VCP-E (980000^02).............................184
VIP
-Е
(980000_03)..............................184
PE (ABC-Studie) (080201_0314).................111
TP
(ABC-Studie) (080201_0314).................111
CCNU/MTX (080202_04)........................115
8.2 NSCLC
Gemcitabin/Cisplatin (080202_03)..............112
Vinorelbin/Carbo (080202_01)..................112
Cisplatin/Vinorelbin NSCLC
adjuvant
(080202_08)...................................113
Paclitaxel (TaxoHJ/Carbo (080202_02)...........113
Paclitaxel (Taxoiej/Carbo
adjuvant
(080202_07)...................................114
Alimta® 2nd Line (080202_09)..................114
Paclitaxel (Taxol®) (080100_03).................106
Docetaxel (080202_06).........................117
Gemcitabin mono (080307_01).................130
Vinorelbin (080401_08).........................140
VCP-E (980000_02).............................184
VIP
-Е
(980000__03)..............................184
CCNU/MTX (080202J34)........................115
8.3 Pleuramesotheliom
Paclitaxel (Taxol^/Carboplatin/Rx
(080203_03)...................................116
Gemcitabin/Cisplatin (080202_03)..............112
Alimta^/Cisplatin (080203_04)
..................117
8.4 Thymuskarzinom
PAC (080204_01)
..............................118
9
Gastrointestinale
Tumoren
9.1 Ösophaguskarzinom
Rx/5-FU/Cisplatin (Naunheim)
(080301ЈЛ)
......120
S-FU/Carboplatin
(080100_01)
..................105
Vinorelbin (080401_08).........................140
9.2 Magenkarzinom
PELF (080302 J)2)..............................121
ELF (080302_01 )...............................121
Vill
Inhaltsverzeichnis
ECF
(080302_04)
...............................122
DCF (080302__05)
...............................123
FOLFIRI (080304_06)
...........................124
9.3 Kolonkarzinom
FOLFIRI
(080304_06)
...........................124
FOLFIRI-Bevacizumab (080304__13)..............124
FOLFOX 4 (080304J38).........................125
FOLFOX 6 (080304_15).........................125
Xelox 2 (080304_14)............................126
Irinotecan-Mono (080304_04)..................126
Irinotecan/Cetuximab (080304_16)..............127
Ardalan (080304_02)...........................127
5-FU/Leukovorin
(»Poon«) (080304_03)
..........128
Capecitabin/Xeloda® (080304_l 0)..............128
Mitomycin-C mono (080304J1}................129
9.4 Analkarzinom
Rx/S-FU/Mitomycin/Cisplatin (Nigro)
(080306_01)...................................129
9.5 Pankreaskarzinom
Gemcitabin (080307_01).......................130
Gemcitabin/Cisplatin (080202_03)..............142
Ardalan (080304_02)...........................127
FOLFOX6(080304_15).........................125
9.6 Cholangiozelluläres Karzinom
Gem0x3
(080309ЈИ)
..........................131
Ardalan (080304_02)...........................127
10 Gynäkologische Tumoren
10.1 Mammakarzinom
FAC (080401_03)
...............................134
FEC (080401_14)...............................134
AC (080401_13)
................................135
EC
(080401_12)................................135
AC/Paclitaxel (Taxol®) (080401_16)..............136
EC/Paclitaxel (Taxol®) (080401
J
5)..............136
CMF+Prednisolon (080401_01).................137
CMF (Bonadonna) (080401 _02).................137
Paclitaxel (Taxol®) (O8010O_03).................106
Paclitaxel (TaxoieyHerceptin (080401 _11 ).......138
Taxotere (080401_07)..........................138
EP (080401_05)................................139
Epirubicin (080401 _06).........................139
Liposomales Doxorubicin/Caelyx®
(080401_10)...................................140
Vinorelbin (080401J58).........................140
VCP-E (980000_02).............................184
VIP
-Е
(980000J)3)..............................184
10.2 Ovarialkarzinom
Cyclo/Carbo (080402JB).......................141
Carboplatin (080402_04).......................141
Paclitaxel (Taxol®) (080100_03).................106
Paclitaxel (Taxoiej+Carboplatin (080402_05) .... 142
Topotecan (080201_05).........................110
Treosulfan (080402_02)
.........................142
Treosulfan
oral (080402_06)....................143
11 Urogenitaltumoren
11.1 Hodenkarzinom
РЕВ (080501_01)...............................
146
PEI (O8O5O1_O3)................................146
PEI+CE/CEC (080501^0409).....................147
PIV+G (080501„02) ............................147
PE (080501 J)4)................................148
Tübinger Studie (Gemcitabin+Oxaliplatirn-
Paclitaxel (Taxol») (080501JM23)...............148
V1C (990000_02)................................196
11.2 Prostatakarzinom
Doxetaxel/Prednisolon (080502_05) ............149
Cyclo/Doxo (080502_03)........................149
Doxorubicin (080502_02).......................150
Cyclophosphamid (080502_01).................150
11.3 Nierenzellkarzinom/Phäochromozytom
HD-IL-2/IFN
α
(080601_01).....................151
HD-IL^-Überwachungsbogen..................152
Cyclo/VD (080601_02)..........................153
11.4 Urothelkarzinom
M-VAC
(080602ЈЛ)
............................154
Gemcitabin/Cisplatin (080202_03)..............112
12 Hauttumoren
12.1
Melanom
CVD/O/lFNa
(»Legna«) (080800_01)
............156
HD-IL^-Überwachungsbogen..................152
Legha Konsolidierung (080800_04).............156
Dacarbazin-mono (080800_02).................157
Fotemustin (080800_03)........................157
CVD (080800_05)...............................158
Lomustin (080201_06)..........................110
13 Sarkome
13.1 Weichteilsarkom
Doxorubicin/Ifosfamid (080901_01).............160
CWS 2002-P (080901_02).......................160
VA ............................................160
VAmod........................................161
IVA
............................................161
IVAmod .......................................162
VAIAMI
........................................162
E-CYC/VBL.....................................163
SL-TECC
I
......................................163
13.2 Ewing-Sarkom
EURO-EWING 99-Studie
(080902ЈШ2)
Bu-Mel........................................164
Me
-Ме
........................................164
VAC
...........................................165
VAI............................................
165
VIDE
..........................................166
13.3 Osteosarkom
EURO-B.O.-Studie (080903_0445)
Therapieübersicht .............................167
Cisplatin/Doxorubicin..........................168
Ifosfamid/Cisplatln ............................168
Ifosfamid/Doxorubicin .........................169
MTX-HD.......................................170
Doxorubicin/Ifosfamid (080901_01) ............160
14 ZNS Tumoren
ТетогоІотіаЯетогіаІ®
(081000JB) ..........172
Lomustin (080201_06) .........................110
Nimustin(081000_01) .........................172
IX
Inhaltsverzeichnis
15 Unbekannter Primärtumor
PCE (081100_01)..............................174
Teil itf Intrakavitäre Chemotherapie
Liqourinstillation »Dreierkombination«
AraC/Dexa/MTX (081200_03)...................176
Liquorinstillation »MTX-Mono« (081200_04) ___176
liposomales Cytarabin/DepoCyte®
(081200_05)...................................177
Bleomycin
intraperikardial(081200_02)
.........177
Teil
IV
Idiotypvakzinierung
Idiovax (970000_0399).........................180
Teil
V
Mobiłisierungschemotherapie
VCP-E (980000_02) ............................184
VIP
-Е
(980000_03)
.............................184
Dexa-BEAM
(980000_08)
.......................186
Cyclo-Mob-ld (980000_05)....................185
Cyclo-Mob^d
(дбОООО^б)
....................186
IEV (980000_09) ...............................186
EVC bei Niereninsuffizienz (980000J 2).........188
VC (980000J1 )................................188
Teil
VI
Hochdosischemotherapien
BEAM (990000_03)
.............................190
BEAM
+ Palifermin
(990000ЈШ2)
..............190
BM (ab 66 Jahre) (990000J3) ..................191
MCLyounger-Studie(060501_0461)............191
Busulfan/Cyclophosphamid/auto (990000_05) ..192
HD Melphalan 200 (990000_0266)..............193
Melphalan 140 (990000_08)....................193
Bu-monop.o. (990000_12) .....................194
Busulfan mono i.v. (990000_15) ................194
ZNS-NHL HD 1
8-65J.
(060507_02) ..............196
VIC (990000_02)
...............................196
Bu-Mel (080902_0202/990000_0202) ...........296
СЕ
/CEC
(990000_0409).........................197
Treosulfan-Studie (Konditionierung
MDS+PBSZT) (990000_0442) ...................198
ATG/Flu/Mel (060509_0266)....................199
Teil
Vil
Supportive
Therapieprotokolle
Amphotericin
В (999999_01)
....................202
Standardisierte Chemotherapieprotokolle
sichere und effektive Behandlung
Das »Blaue Buch« ist eine Zusammenstellung von über 300 standar¬
disierten und detaillierten Behandlungsprotokollen zur
Chemotherapiebehandlung von Tumorpatienten auf dem neuesten
Stand gesicherter medizinischer Erkenntnisse, die sich seit Jahren in
der täglichen Praxis bewährt haben.
Auf einen Blick finden Sie
Detailinformationen zur Chemotherapie
α
ßegleitmedikation
<=
Supportive
Therapie
=· Nebenwirkungen
■=■ Kontrollen
■=> Nlotfallsituationen
Fundiertes und therapieorientiertes Nachschlagewerk für Ärzte,
Plegende
und Apotheker im Bereich der internistischen
Hämatologie und Ontotogie.
Zusätzlich zur Druckversion lum Nachschlugen und Ausdrucken
■= individualisierte Patientenkurvenblätter für dem täglichen
Gebrauch in der Praxis und auf Station
■= Chemotherapiebestellformulare
fir
den Therapieauftrag
an die Apotheke
<=> standardisierte Vbrgehensweisen
=
Clinical Pathways
<= Auffiärungen und Einverständniserklärungen
<=: Informationsblätter für Patienten
■— Patienten-Therapiebegleiter
Systemanforderungen
Windows:
Win98
SE,
WinNT, WinME,
Win2000, Win XP oder Win2003
plus Adobe Acrobat Reader 6.x
Macintosh:
OS 9.x oder OS
X
plus Adobe
Acrobat Reader 6.x
Sowie alle Unixsysteme mit
Adobe Acrobat Reader 6.x oder
jünger.
|
| adam_txt |
Inhaltsverzeichnis
Vorwort.
V
Autorenverzeichnis.
X
Abkürzungsverzeichnis.
XI
Einleitung.XIII
Teii
І
Hämatologische Neoplasien
1 Akute Leukämien
1.1 ALL
GMALL B-ALL/NHL 2002 (060101_0360) .4
GMALL 07/03 (060101_0400).9
GMALL 07/2003 + Rituximab (060101_0458). 15
Imatinib bei Ph+ALL (060101_0521 ).20
Busulfan/Cyclophosphamid/auto
(990000_05).196
1.2 AML
AML99(060102_0155)
IVA-1.23
IVA-2.23
Flag-Ida
.24
ID-AraC/DNR.24
HD-AraC/DNR.25
Intergroup: Induktion (AraC/DNR).25
Intergroup: Postremission (HD-AraC).26
S-HAM (060102_01).26
Ida/Ara 3+7 (060102_02).27
Ida/Ara 3+4 (060102_03).27
MICE
(060102_05) .28
mini-ICE (060102_06) .28
APL2000 (060102_07).29
APL2000 Studie (060102_0220).32
Decitabine (060102_0331).37
Mylotarge-Studie (060102_0391).39
AMLSG 7-04-Studie (060102_0478) .41
Busulfan/Cyclophosphamid/auto
(990000_05).192
Busulfan mono p.o. (990000_12).194
Busulfan mono i.v. (990000_15).
1
94
2 MDS
Decitabine/DAC (EORTC-Studie)
(060200ЈШЗ)
.48
Azacytidine (060200_01).48
Treosulfan-Studiefremdallogen/familiär
(990000J442) .198
3 MPS
3.1 OMF
Thalidomid/Prednison (060510_01).50
3.2 CML
GEIST-Studie (060510_0439) .50
Busulfan/Cyclophosphamid/auto (990000_05). 192
4 Hodgkin-Lymphome
ABVD
(060400ЈЛ)
.56
BEACOPP-Il-Basis (060400 J)153).56
BEACOPP-ll-gesteigert (060400_0154) .57
HD-13 (060400_0388).57
HD-14 (060400JB89).59
HD-15 (060400_0390).61
PVAG (060400_0446).62
Vinblastin (060400_02).62
Bendamustin (060501_11) .72
Lomustin (080201_06).110
BEAM (990000_03)
.190
BEAM
+
Palìfermin (990000_0322)
.190
BM (ab 66 Jahre) (990000J3).191
5 Non-Hodgkin-Lymphome
CHOP
(0б0501_02).
67
CORAL-Studie (060501_0407).72
GMALL B-ALL/NHL 2002
(ОбОЮЦВбО)
.4
FludyCy (MDAnderson) (060502_03).80
VCP-E (980000_02).184
VIP
-Е
(980000_03).184
Cyclo-Mob-Id (980000_05).185
Cyclo-Mob^d (980000_06).185
BEAM (990000_03)
.190
BEAM
+ Palifermin
(990000ЈШ2)
.190
BM (ab 66 Jahre) (990000_13).191
5.1 Mantelzelllymphom
MCLyounger-Studie (060501_0461).191
Temsirolimus (060505J3459).86
5.2 Hochmaligne NHL
VACOP-B
(OóOSOIJJI)
.66
CHOP (060501_02)
.67
Mabtherae-CHOPM (O6O5O1_O5).68
CHOP-14 (060501_09).68
CHOP gesplittet
(060501_12).69
R-CHOP (060501_14).69
COP
(060501_03).
70
HD-Pred
(060501_06).
70
DHAP
(060501_08)
.71
Ixoten® (060501_10)
.71
Bendamustin
(0б0501_Л
).72
CORAL
Studie (060501_0407) .72
MCL
younger
(060501_0461).192
Flyer Studie (060501_0504) .74
Unfolder Studie
(0б0501_0505)
.76
FludyCy (MDAnderson) (060502_03).80
Fludara«/Endoxan®/Rituximab
(060502_06).80
5.3 CLL
Knospe (060502_01).79
Fludarabin (060502_02).79
FludyCy (MDAnderson) (060502_03).80
Fludarae/Endoxans/Rituximab (060502_06).80
COP
(060501_03).
70
Inhaltsverzeichnis
VII
Bendamustin
(0б0501_1
1).72
MabCampath®
(0б0502_04)
.81
MabCampath
Studie
(0б0502_0372)
.81
2-CDA
(0б0504_01)
.83
5.4
PLL
CHOP (060501_02)
.67
FludyCy (MDAnderson) (060502_03)
.80
Fludarae/Endoxane/Rituximab (060502_06)
.80
2-CDA
(060504ЈЛ)
.83
5.5 Haarzellleukämie
2-CDA
(060504ЈЛ)
.83
Pentostatin (060504_02
).83
Cladribine/Rituximab (060504_0473)
.84
5.6
Follikulare NHL
Rituximab (060505_01)
.85
CHOP (060501_02)
.67
Münchner Lymphomstudie
(MabtheraeCHOP)
(060505_0206)
.85
VACOP-B
(0605001).66
COP (060501_03)
.70
Zevalin®
+
Rituximab (060505_0443)
.86
Knospe (060502_01) .79
Fludarabin (060502_02)
.79
Fludara®/Endoxan®/Rituximab
(0б0502_0б)
.80
5.7
Kutané
Т
-NHL
CHOP (060501_02)
.67
COP (060501JB)
.70
Fludarabin (060502_02)
.79
2-CDA
(060504ЈЛ)
.83
5.8
ZNS-NHL
ZNS-NHL HD 1
8-65J. (060507_02)
.196
ZNS-NHL >65J.
(060507ЈЛ67)
.89
ZNS-NHL MTX
(060507_02)
.88
ZNS-NHL AraCAhiotepa (060507_02)
.88
R-MCP (060507_03)
.89
MTX 8g
Hochberg (060507_01).90
ZNS-NHL Leukovorin Rescue
.90
5.9
Multiples Myelom/Amyloidose
HD-Dexa (060509_02)
.91
Alexanian (060509_01)
.91
Melphalan (060509_03)
.92
Thalidomid/Dexamethason (060509_07)
.92
CTD (060509_08)
.93
Lenalidomid/Dexamethason (060509_14)
.93
Velcade^/Bortezomib (060509_1
0).94
Bortezomib/Dexamethason (060509_1
2).94
DeCyBo (060509_1
1).95
VAD
(060509_04)
.
95
Induktion
(Cyclo) (060509_05)
.96
ID
.96
DSMM Xla (060509_0497)
.97
Palladini Protokoll (060509_13).98
Amyloidose (HD-Dexa/lnterferon-a)
(060509_09)
.98
Bendamustin
(060501_11)
.72
Cyclo-Mob-Id (980000_05)
.185
Cyclo-Mob^d (980000_06)
.185
IEV
<
60J. (980000_09)
.186
HD
Melphalan
.95
ATG/Flu/Mel
.200
Aplastische Anämien
CyA/ALG/Prednisolon (070200_01)
.100
Teil 11 Solide Tumoren
7 Kopf-Hals Tumoren
Doxetaxel/Cisplatin (080100_06) .104
S-FU/Cisplatin (080100_04) .104
S-FU/Carboplatin (080100_01).105
EMB (080100_02) .105
Taxol® (080100_03).106
8 Thorakale Tumoren
8.1 SCLC
TEC
(080201 _07).108
Epi-CO (080201 _01 ).108
Cisplatin/Etoposid
limited disease
(080201_02).109
CE
(080201 _03).109
Topotecan (080201_05).110
Lomustin (080201_06).110
VCP-E (980000^02).184
VIP
-Е
(980000_03).184
PE (ABC-Studie) (080201_0314).111
TP
(ABC-Studie) (080201_0314).111
CCNU/MTX (080202_04).115
8.2 NSCLC
Gemcitabin/Cisplatin (080202_03).112
Vinorelbin/Carbo (080202_01).112
Cisplatin/Vinorelbin NSCLC
adjuvant
(080202_08).113
Paclitaxel (TaxoHJ/Carbo (080202_02).113
Paclitaxel (Taxoiej/Carbo
adjuvant
(080202_07).114
Alimta® 2nd Line (080202_09).114
Paclitaxel (Taxol®) (080100_03).106
Docetaxel (080202_06).117
Gemcitabin mono (080307_01).130
Vinorelbin (080401_08).140
VCP-E (980000_02).184
VIP
-Е
(980000_03).184
CCNU/MTX (080202J34).115
8.3 Pleuramesotheliom
Paclitaxel (Taxol^/Carboplatin/Rx
(080203_03).116
Gemcitabin/Cisplatin (080202_03).112
Alimta^/Cisplatin (080203_04)
.117
8.4 Thymuskarzinom
PAC (080204_01)
.118
9
Gastrointestinale
Tumoren
9.1 Ösophaguskarzinom
Rx/5-FU/Cisplatin (Naunheim)
(080301ЈЛ)
.120
S-FU/Carboplatin
(080100_01)
.105
Vinorelbin (080401_08).140
9.2 Magenkarzinom
PELF (080302 J)2).121
ELF (080302_01 ).121
Vill
Inhaltsverzeichnis
ECF
(080302_04)
.122
DCF (080302_05)
.123
FOLFIRI (080304_06)
.124
9.3 Kolonkarzinom
FOLFIRI
(080304_06)
.124
FOLFIRI-Bevacizumab (080304_13).124
FOLFOX 4 (080304J38).125
FOLFOX 6 (080304_15).125
Xelox 2 (080304_14).126
Irinotecan-Mono (080304_04).126
Irinotecan/Cetuximab (080304_16).127
Ardalan (080304_02).127
5-FU/Leukovorin
(»Poon«) (080304_03)
.128
Capecitabin/Xeloda® (080304_l 0).128
Mitomycin-C mono (080304J1}.129
9.4 Analkarzinom
Rx/S-FU/Mitomycin/Cisplatin (Nigro)
(080306_01).129
9.5 Pankreaskarzinom
Gemcitabin (080307_01).130
Gemcitabin/Cisplatin (080202_03).142
Ardalan (080304_02).127
FOLFOX6(080304_15).125
9.6 Cholangiozelluläres Karzinom
Gem0x3
(080309ЈИ)
.131
Ardalan (080304_02).127
10 Gynäkologische Tumoren
10.1 Mammakarzinom
FAC (080401_03)
.134
FEC (080401_14).134
AC (080401_13)
.135
EC
(080401_12).135
AC/Paclitaxel (Taxol®) (080401_16).136
EC/Paclitaxel (Taxol®) (080401
J
5).136
CMF+Prednisolon (080401_01).137
CMF (Bonadonna) (080401 _02).137
Paclitaxel (Taxol®) (O8010O_03).106
Paclitaxel (TaxoieyHerceptin (080401 _11 ).138
Taxotere (080401_07).138
EP (080401_05).139
Epirubicin (080401 _06).139
Liposomales Doxorubicin/Caelyx®
(080401_10).140
Vinorelbin (080401J58).140
VCP-E (980000_02).184
VIP
-Е
(980000J)3).184
10.2 Ovarialkarzinom
Cyclo/Carbo (080402JB).141
Carboplatin (080402_04).141
Paclitaxel (Taxol®) (080100_03).106
Paclitaxel (Taxoiej+Carboplatin (080402_05) . 142
Topotecan (080201_05).110
Treosulfan (080402_02)
.142
Treosulfan
oral (080402_06).143
11 Urogenitaltumoren
11.1 Hodenkarzinom
РЕВ (080501_01).
146
PEI (O8O5O1_O3).146
PEI+CE/CEC (080501^0409).147
PIV+G (080501„02) .147
PE (080501 J)4).148
Tübinger Studie (Gemcitabin+Oxaliplatirn-
Paclitaxel (Taxol») (080501JM23).148
V1C (990000_02).196
11.2 Prostatakarzinom
Doxetaxel/Prednisolon (080502_05) .149
Cyclo/Doxo (080502_03).149
Doxorubicin (080502_02).150
Cyclophosphamid (080502_01).150
11.3 Nierenzellkarzinom/Phäochromozytom
HD-IL-2/IFN
α
(080601_01).151
HD-IL^-Überwachungsbogen.152
Cyclo/VD (080601_02).153
11.4 Urothelkarzinom
M-VAC
(080602ЈЛ)
.154
Gemcitabin/Cisplatin (080202_03).112
12 Hauttumoren
12.1
Melanom
CVD/O/lFNa
(»Legna«) (080800_01)
.156
HD-IL^-Überwachungsbogen.152
Legha Konsolidierung (080800_04).156
Dacarbazin-mono (080800_02).157
Fotemustin (080800_03).157
CVD (080800_05).158
Lomustin (080201_06).110
13 Sarkome
13.1 Weichteilsarkom
Doxorubicin/Ifosfamid (080901_01).160
CWS 2002-P (080901_02).160
VA .160
VAmod.161
IVA
.161
IVAmod .162
VAIAMI
.162
E-CYC/VBL.163
SL-TECC
I
.163
13.2 Ewing-Sarkom
EURO-EWING 99-Studie
(080902ЈШ2)
Bu-Mel.164
Me
-Ме
.164
VAC
.165
VAI.
165
VIDE
.166
13.3 Osteosarkom
EURO-B.O.-Studie (080903_0445)
Therapieübersicht .167
Cisplatin/Doxorubicin.168
Ifosfamid/Cisplatln .168
Ifosfamid/Doxorubicin .169
MTX-HD.170
Doxorubicin/Ifosfamid (080901_01) .160
14 ZNS Tumoren
ТетогоІотіаЯетогіаІ®
(081000JB) .172
Lomustin (080201_06) .110
Nimustin(081000_01) .172
IX
Inhaltsverzeichnis
15 Unbekannter Primärtumor
PCE (081100_01).174
Teil itf Intrakavitäre Chemotherapie
Liqourinstillation »Dreierkombination«
AraC/Dexa/MTX (081200_03).176
Liquorinstillation »MTX-Mono« (081200_04) _176
liposomales Cytarabin/DepoCyte®
(081200_05).177
Bleomycin
intraperikardial(081200_02)
.177
Teil
IV
Idiotypvakzinierung
Idiovax (970000_0399).180
Teil
V
Mobiłisierungschemotherapie
VCP-E (980000_02) .184
VIP
-Е
(980000_03)
.184
Dexa-BEAM
(980000_08)
.186
Cyclo-Mob-ld (980000_05).185
Cyclo-Mob^d
(дбОООО^б)
.186
IEV (980000_09) .186
EVC bei Niereninsuffizienz (980000J 2).188
VC (980000J1 ).188
Teil
VI
Hochdosischemotherapien
BEAM (990000_03)
.190
BEAM
+ Palifermin
(990000ЈШ2)
.190
BM (ab 66 Jahre) (990000J3) .191
MCLyounger-Studie(060501_0461).191
Busulfan/Cyclophosphamid/auto (990000_05) .192
HD Melphalan 200 (990000_0266).193
Melphalan 140 (990000_08).193
Bu-monop.o. (990000_12) .194
Busulfan mono i.v. (990000_15) .194
ZNS-NHL HD 1
8-65J.
(060507_02) .196
VIC (990000_02)
.196
Bu-Mel (080902_0202/990000_0202) .296
СЕ
/CEC
(990000_0409).197
Treosulfan-Studie (Konditionierung
MDS+PBSZT) (990000_0442) .198
ATG/Flu/Mel (060509_0266).199
Teil
Vil
Supportive
Therapieprotokolle
Amphotericin
В (999999_01)
.202
Standardisierte Chemotherapieprotokolle
sichere und effektive Behandlung
Das »Blaue Buch« ist eine Zusammenstellung von über 300 standar¬
disierten und detaillierten Behandlungsprotokollen zur
Chemotherapiebehandlung von Tumorpatienten auf dem neuesten
Stand gesicherter medizinischer Erkenntnisse, die sich seit Jahren in
der täglichen Praxis bewährt haben.
Auf einen Blick finden Sie
Detailinformationen zur Chemotherapie
α
ßegleitmedikation
<=
Supportive
Therapie
'=· Nebenwirkungen
■=■ Kontrollen
■=> Nlotfallsituationen
Fundiertes und therapieorientiertes Nachschlagewerk für Ärzte,
Plegende
und Apotheker im Bereich der internistischen
Hämatologie und Ontotogie.
Zusätzlich zur Druckversion lum Nachschlugen und Ausdrucken
■=' individualisierte Patientenkurvenblätter für dem täglichen
Gebrauch in der Praxis und auf Station
■= Chemotherapiebestellformulare
fir
den Therapieauftrag
an die Apotheke
<=> standardisierte Vbrgehensweisen
=
Clinical Pathways
<= Auffiärungen und Einverständniserklärungen
<=: Informationsblätter für Patienten
■— Patienten-Therapiebegleiter
Systemanforderungen
Windows:
Win98
SE,
WinNT, WinME,
Win2000, Win XP oder Win2003
plus Adobe Acrobat Reader 6.x
Macintosh:
OS 9.x oder OS
X
plus Adobe
Acrobat Reader 6.x
Sowie alle Unixsysteme mit
Adobe Acrobat Reader 6.x oder
jünger. |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Berger, Dietmar Paul Engelhardt, Monika 1966- Mertelsmann, Roland 1944- |
| author_GND | (DE-588)111674808 (DE-588)113263538 (DE-588)122802187 |
| author_facet | Berger, Dietmar Paul Engelhardt, Monika 1966- Mertelsmann, Roland 1944- |
| author_role | aut aut aut |
| author_sort | Berger, Dietmar Paul |
| author_variant | d p b dp dpb m e me r m rm |
| building | Verbundindex |
| bvnumber | BV023353369 |
| classification_rvk | XH 1503 XH 3209 YC 2109 YC 2303 |
| ctrlnum | (OCoLC)76873842 (DE-599)BVBBV023353369 |
| dewey-full | 616.994061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994061 |
| dewey-search | 616.994061 |
| dewey-sort | 3616.994061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| edition | 1. Aufl., 1. korrigierter Nachdr. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02945nam a22006611c 4500</leader><controlfield tag="001">BV023353369</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080813 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080619s2007 gw ad|| |||| 00||| ger d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783540452829</subfield><subfield code="9">978-3-540-45282-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540452826</subfield><subfield code="9">3-540-45282-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">354045282X</subfield><subfield code="9">3-540-45282-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)76873842</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023353369</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994061</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 1503</subfield><subfield code="0">(DE-625)152870:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3209</subfield><subfield code="0">(DE-625)152888:12915</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 2109</subfield><subfield code="0">(DE-625)153197:12915</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 2303</subfield><subfield code="0">(DE-625)153200:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Berger, Dietmar Paul</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)111674808</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Das Blaue Buch 2007 - 2008</subfield><subfield code="b">Chemotherapie-Manual Hämatologie und internistische Onkologie</subfield><subfield code="c">Dietmar Berger ; Monika Engelhardt ; Roland Mertelsmann</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. Aufl., 1. korrigierter Nachdr.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Heidelberg</subfield><subfield code="b">Springer</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVIII, 202 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield><subfield code="e">1 CD-ROM (12 cm)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Protocols</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Onkologie</subfield><subfield code="0">(DE-588)4075658-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Blutkrankheit</subfield><subfield code="0">(DE-588)4007281-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hämatologie</subfield><subfield code="0">(DE-588)4022796-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Blutkrankheit</subfield><subfield code="0">(DE-588)4007281-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Hämatologie</subfield><subfield code="0">(DE-588)4022796-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Onkologie</subfield><subfield code="0">(DE-588)4075658-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Engelhardt, Monika</subfield><subfield code="d">1966-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)113263538</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mertelsmann, Roland</subfield><subfield code="d">1944-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)122802187</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016536946&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016536946&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Klappentext</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016536946</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection> |
| id | DE-604.BV023353369 |
| illustrated | Illustrated |
| index_date | 2024-07-02T21:06:06Z |
| indexdate | 2024-07-09T21:16:39Z |
| institution | BVB |
| isbn | 9783540452829 3540452826 |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016536946 |
| oclc_num | 76873842 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XVIII, 202 S. Ill., graph. Darst. 1 CD-ROM (12 cm) |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Springer |
| record_format | marc |
| spelling | Berger, Dietmar Paul Verfasser (DE-588)111674808 aut Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie Dietmar Berger ; Monika Engelhardt ; Roland Mertelsmann 1. Aufl., 1. korrigierter Nachdr. Heidelberg Springer 2007 XVIII, 202 S. Ill., graph. Darst. 1 CD-ROM (12 cm) txt rdacontent n rdamedia nc rdacarrier Antineoplastic Agents therapeutic use Antineoplastic Protocols Neoplasms drug therapy Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Onkologie (DE-588)4075658-0 gnd rswk-swf Blutkrankheit (DE-588)4007281-2 gnd rswk-swf Hämatologie (DE-588)4022796-0 gnd rswk-swf Blutkrankheit (DE-588)4007281-2 s Krebs Medizin (DE-588)4073781-0 s DE-604 Hämatologie (DE-588)4022796-0 s Onkologie (DE-588)4075658-0 s Chemotherapie (DE-588)4127083-6 s 1\p DE-604 Engelhardt, Monika 1966- Verfasser (DE-588)113263538 aut Mertelsmann, Roland 1944- Verfasser (DE-588)122802187 aut Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016536946&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016536946&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA Klappentext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Berger, Dietmar Paul Engelhardt, Monika 1966- Mertelsmann, Roland 1944- Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie Antineoplastic Agents therapeutic use Antineoplastic Protocols Neoplasms drug therapy Krebs Medizin (DE-588)4073781-0 gnd Chemotherapie (DE-588)4127083-6 gnd Onkologie (DE-588)4075658-0 gnd Blutkrankheit (DE-588)4007281-2 gnd Hämatologie (DE-588)4022796-0 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4127083-6 (DE-588)4075658-0 (DE-588)4007281-2 (DE-588)4022796-0 |
| title | Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie |
| title_auth | Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie |
| title_exact_search | Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie |
| title_exact_search_txtP | Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie |
| title_full | Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie Dietmar Berger ; Monika Engelhardt ; Roland Mertelsmann |
| title_fullStr | Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie Dietmar Berger ; Monika Engelhardt ; Roland Mertelsmann |
| title_full_unstemmed | Das Blaue Buch 2007 - 2008 Chemotherapie-Manual Hämatologie und internistische Onkologie Dietmar Berger ; Monika Engelhardt ; Roland Mertelsmann |
| title_short | Das Blaue Buch 2007 - 2008 |
| title_sort | das blaue buch 2007 2008 chemotherapie manual hamatologie und internistische onkologie |
| title_sub | Chemotherapie-Manual Hämatologie und internistische Onkologie |
| topic | Antineoplastic Agents therapeutic use Antineoplastic Protocols Neoplasms drug therapy Krebs Medizin (DE-588)4073781-0 gnd Chemotherapie (DE-588)4127083-6 gnd Onkologie (DE-588)4075658-0 gnd Blutkrankheit (DE-588)4007281-2 gnd Hämatologie (DE-588)4022796-0 gnd |
| topic_facet | Antineoplastic Agents therapeutic use Antineoplastic Protocols Neoplasms drug therapy Krebs Medizin Chemotherapie Onkologie Blutkrankheit Hämatologie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016536946&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016536946&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT bergerdietmarpaul dasblauebuch20072008chemotherapiemanualhamatologieundinternistischeonkologie AT engelhardtmonika dasblauebuch20072008chemotherapiemanualhamatologieundinternistischeonkologie AT mertelsmannroland dasblauebuch20072008chemotherapiemanualhamatologieundinternistischeonkologie |